Sugi Predict

Sugi Predict / Compounds / SCHEMBL41941

SCHEMBL41941

SCHEMBL41941

CS(=O)(=O)c1cccc(C=O)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ UNG P13051 1/20 0.42
▸ CYP2A6 P11509 1/20 0.41
▸ CREBBP Q92793 1/20 0.39
▸ NAT1 P18440 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ LOX P28300 1/20 0.38
▸ LOXL2 Q9Y4K0 1/20 0.38
▸ AKR1C3 P42330 4/20 0.38
▸ SRC P12931 1/20 0.38
▸ AKR1C2 P52895 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30402657 1.00 CA12 (0.47) CA12CA1CA2CA9ALDH1A1
SCHEMBL3465180 0.85 CREBBP (0.40) CA1CA2ALDH1A1CREBBPSMN1; SMN2
SCHEMBL3465179 0.84 DRD2 (0.42) ALDH1A1CREBBPSMN1; SMN2LOXLOXL2
SCHEMBL6853269 0.83 ALDH1A1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL31604493 0.83 ALDH1A1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL11330739 0.82 TDP1 (0.50) ALDH1A1CREBBPSMN1; SMN2LOXLOXL2
SCHEMBL1435257 0.81 CCNB2 (0.53) ALDH1A1CREBBPLOXLOXL2
SCHEMBL29584749 0.81 CCNB2 (0.53) ALDH1A1CREBBPLOXLOXL2
SCHEMBL1435256 0.81 CCNB2 (0.53) ALDH1A1CREBBPLOXLOXL2
SCHEMBL16712226 0.81 CA1 (0.49) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113481188-B Threonine aldolase mutant and application thereof in preparation of substituted phenylserine derivative 王喆明 2023-03-24 — — CN claimed
CN-113481188-A Threonine aldolase mutant and application thereof in preparation of substituted phenylserine derivative 王喆明 2021-10-08 — — CN claimed
CN-109402098-B Threonine aldolase, mutant and application of mutant in preparation of substituted phenylserine derivative 王喆明 2021-09-17 — — CN claimed
WO-2020102575-A1 HETEROCYCLIC AMINOTHIAZOLES AND USES THEREOF INCEPTION IBD, INC. (US) 2020-05-22 — — WO claimed
US-12583855-B2 RET selective inhibitor, preparation method therefor and use thereof Shouyao Holdings (beijing) Co., Ltd. (CN) 2026-03-24 — — US disclosed
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 — — EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 — — US disclosed
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
CN-119899122-A Cyclobutylmethyl and phenyl substituted curcumin derivative and preparation method and application thereof 常州大学 2025-04-29 — — CN disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed
US-6071936-A ANTIINFLAMMATORY AGENTS ANTIPYRETICS, ANALGESICS, ANTICARCINOGENIC AGENTS, SIDE EFFECT REDUCTION MERCK FROSST CANADA & CO. (CA) 2000-06-06 — — US disclosed
CN-1252070-A 5,7-disubstituted 4-aminopyrido [2,3,-d] pyrimidine compounds and their use as adenosine kinase inhibitors ABBOTT LAB (US) 2000-05-03 — — CN disclosed
US-6020379-A Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-02-01 — — US disclosed
US-5861419-A ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT MERCK FROSST CANAD, INC. (CA) 1999-01-19 — — US disclosed
US-5037824-A Cardiotonic, antiischemic agents FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1991-08-06 — — US disclosed
EP-0387070-A2 N-Containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-09-12 — — EP disclosed
US-4021434-A CEREBRAL VASODILATORS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1977-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583855-B2 RET selective inhibitor, preparation method therefor and use thereof RET, ROR1, TMPRSS11D CA12 1898/4885CA1 2671/4885CA2 1103/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CA12 1608/4885CA1 1323/4885CA2 1787/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CA12 1608/4885CA1 1323/4885CA2 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.